Business News

AstraZeneca sees profits surge despite Chinese import tax allegations


Profit after tax rose to $7 billion last year, up from $6 billion in 2023, the company said, noting a sharp increase in sales of cancer medicines. Read More

https://fortune.com/img-assets/wp-content/uploads/2025/02/GettyImages-1247540867-e1738838327829.jpg?resize=1200,600

2025-02-06 11:01:10

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button